Titan Pharmaceuticals, Inc. (TTNP) Financial Ratios
30 years of historical data (1995–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.13
↓-90% vs avg
5yr avg: 10.99
30Y Low0.9·High175.9
ROE
↑
-103.6%
↓+67% vs avg
5yr avg: -315.6%
30Y Low-389%·High169%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TTNP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Titan Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $3M | $6M | $10M | $41M | $131M | $186M | $150M | $565M | $1.7B | $1.8B |
| Enterprise Value | $1M | $99740 | $9000 | $8M | $35M | $127M | $186M | $145M | $564M | $1.7B | $1.8B |
| P/E Ratio → | -0.59 | — | — | — | — | — | — | — | — | 399.89 | — |
| P/S Ratio | — | — | 6204.00 | 174.64 | 26.71 | 27.17 | 51.65 | 25.40 | 2625.78 | 113.95 | 1065.64 |
| P/B Ratio | 1.13 | 1.20 | 0.93 | 7.69 | 7.93 | 37.22 | 130.15 | 21.98 | 658.74 | 130.13 | 254.75 |
| P/FCF | — | — | — | — | — | — | — | — | — | 280.40 | — |
| P/OCF | — | — | — | — | — | — | — | — | — | 272.78 | — |
P/E links to full P/E history page with 30-year chart
TTNP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 9.00 | 128.81 | 22.95 | 26.22 | 51.43 | 24.56 | 2621.42 | 113.02 | 1060.94 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 360.72 | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | 392.03 | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | 278.11 | — |
TTNP Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -17058.3% to -727700.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -103.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | -226.7% | 87.0% | 90.2% | 64.3% | 90.9% | -4387.4% | 59.3% | -179.8% |
| Operating Margin | — | — | -727700.0% | -17058.3% | -613.0% | -151.9% | -466.5% | -139.8% | -6745.1% | 28.8% | -404.5% |
| Net Profit Margin | — | — | -556900.0% | -16961.7% | -531.7% | -428.4% | -445.6% | -152.6% | -6654.4% | 34.1% | -675.0% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -103.6% | -103.6% | -139.1% | -313.1% | -187.2% | -835.0% | -389.4% | -234.7% | -203.7% | 50.9% | -144.6% |
| ROA | -85.5% | -85.5% | -91.7% | -168.9% | -100.9% | -235.4% | -136.2% | -78.5% | -103.8% | 32.1% | -66.1% |
| ROIC | -12206.3% | -12206.3% | — | — | — | — | -1010.2% | -700.7% | — | — | — |
| ROCE | -100.4% | -100.4% | -180.3% | -303.1% | -203.6% | -150.2% | -203.4% | -109.6% | -158.9% | 39.0% | -59.8% |
TTNP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $3M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.09 | 0.14 | 0.06 | 0.23 | 3.10 | 0.63 | 7.68 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.16 | -0.93 | -2.02 | -1.12 | -1.30 | -0.55 | -0.73 | -1.09 | -1.06 | -1.12 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -2.97 | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | -2.29 | — |
| Interest Coverage | — | — | — | — | — | -9.56 | -17.42 | -9.32 | -39.30 | 117.38 | — |
Net cash position: cash ($3M) exceeds total debt ($0)
TTNP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Titan Pharmaceuticals, Inc.'s current ratio of 6.05x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.37x to 6.05x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.05 | 6.05 | 5.55 | 1.37 | 2.71 | 1.74 | 2.31 | 3.85 | 1.86 | 3.67 | 2.52 |
| Quick Ratio | 6.05 | 6.05 | 5.55 | 1.33 | 2.60 | 1.66 | 2.03 | 3.49 | 1.86 | 3.67 | 2.52 |
| Cash Ratio | 5.86 | 5.86 | 4.68 | 1.12 | 2.26 | 1.28 | 1.45 | 2.69 | 1.69 | 2.88 | 1.62 |
| Asset Turnover | — | — | 0.00 | 0.01 | 0.19 | 0.60 | 0.38 | 0.42 | 0.02 | 0.81 | 0.13 |
| Inventory Turnover | 1.85 | — | — | 1.85 | 0.68 | 1.44 | 1.29 | 0.43 | — | — | — |
| Days Sales Outstanding | — | — | 381790.00 | 219.00 | 26.79 | 66.69 | 44.27 | 113.37 | 110.35 | 86.91 | 920.25 |
TTNP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Titan Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 0.2% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | 0.3% | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | 0.4% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $899000 | $752000 | $671700 | $2M | $2M | $2M | $189598 | $117908 | $119208 | $111404 |
Peer Comparison
Compare TTNP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TTNPYou | $4M | -0.6 | — | — | — | — | -103.6% | -12206.3% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 MTLS | $321M | 35.7 | 8.0 | 30.0 | 57.1% | 1.9% | 2.9% | 2.0% | 2.6 |
 ORMP | $160M | -8.3 | — | — | — | — | -12.4% | -6.5% | — |
 AVDL | $2B | -42.4 | — | — | 91.0% | -25.1% | -60.4% | -76.3% | — |
 COLL | $1B | 22.7 | 4.8 | 3.9 | 59.3% | 24.0% | 23.7% | 14.0% | 2.3 |
 MNKD | $1B | 177.5 | 29.3 | 80.1 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 PAHC | $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 PCRX | $930M | 147.8 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See TTNP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TTNP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TTNP vs NKTR
Side-by-side business, growth, and profitability comparison vs Nektar Therapeutics.
Start ComparisonTTNP — Frequently Asked Questions
Quick answers to the most common questions about buying TTNP stock.
What is Titan Pharmaceuticals, Inc.'s P/E ratio?
Titan Pharmaceuticals, Inc.'s current P/E ratio is -0.6x. The historical average is 127.2x.
What is Titan Pharmaceuticals, Inc.'s ROE?
Titan Pharmaceuticals, Inc.'s return on equity (ROE) is -103.6%. The historical average is -109.1%.
Is TTNP stock overvalued?
Based on historical data, Titan Pharmaceuticals, Inc. is trading at a P/E of -0.6x. Compare with industry peers and growth rates for a complete picture.